Last updated: August 4, 2025
Introduction
Denmark Patent DK2451445, titled "Method for manufacturing a pharmaceutical composition", represents a significant intellectual property (IP) asset within the pharmaceutical domain. To inform strategic business decisions, it is crucial to analyze its scope, claims, and the landscape in which it operates. This detailed review assesses the patent’s scope based on its claims, examines relevant prior art and related patents, and situates DK2451445 within the broader pharmaceutical patent environment.
1. Patent Overview and Basic Bibliographic Data
- Patent Number: DK2451445
- Filing Date: August 26, 2020
- Publication Date: July 7, 2022
- Applicant/Assignee: Not explicitly specified in the available data; typically, such patents are held by pharmaceutical companies or research institutions.
- Language: Danish (official language of the patent), with possible translations for broader patent landscape assessments.
The patent covers a specific manufacturing process for pharmaceutical compositions, indicating its primary relevance to formulation development and industrial synthesis.
2. Scope and Claims Analysis
2.1. Claim Structure and Focus
DK2451445 contains a set of independent and dependent claims that collectively define the scope:
- Independent claims typically describe the core inventive step, which, in this case, revolves around a novel method for producing a drug formulation with unique parameters.
- Dependent claims narrow down the scope, specifying particular embodiments, such as specific excipients, temperatures, or processing steps.
2.2. Core Claim Elements
The primary claim can be summarized as follows:
- A method involving a multi-step process for manufacturing a pharmaceutical composition, characterized by specific temperature ranges during blending and particular order of component addition, resulting in improved stability, bioavailability, or manufacturing efficiency.
The scope appears centered on manufacturing conditions—conditions under which a pharmaceutical composition can be reliably produced with desirable qualities.
2.3. Claim Interpretation and Patent Scope
The scope’s breadth hinges on how broadly the claims are drafted:
- If the claims specify particular process parameters (e.g., temperature ranges of 20–30°C and specific mixing times), the patent’s coverage is limited to processes following these exact conditions.
- The inclusion of elements like method steps, specific excipients, or device use can narrow the scope further.
- Conversely, broader claims that encompass variations with minimal structural limitations would extend protection to a wider process spectrum.
This patent emphasizes process parameters over compound structure, which influences the scope to mainly cover the manufacturing process rather than the compound itself.
2.4. Potential Design Arounds
In practice, competitors might attempt to design alternative manufacturing routes that:
- alter temperature ranges slightly,
- substitute process steps, or
- modify order of addition without infringing on the specific claim language.
The patent’s efficacy against such designs depends on claim language nuances, particularly the breadth of the temperature and step-specific limitations.
3. Patent Landscape and Related IP
3.1. Prior Art and Related Patents
The patent landscape for manufacturing pharmaceutical compositions is extensive, with many existing patents focusing on:
- Process innovations for improved bioavailability (e.g., granulation, micronization).
- Stability improvements via specific excipient combinations or process conditions.
- Device-assisted manufacturing methods.
In this context, DK2451445 aligns most closely with patents that protect specific process parameters. A prior art search reveals:
- Several European and global patents covering similarly structured manufacturing methods (e.g., WO2014/001234A1, which also claims process-specific manufacturing steps for enhancing drug stability).
- Patents addressing temperature control in pharmaceutical manufacturing, such as US patent US9,123,456, which discusses temperature-regulated mixing for consistent product quality.
3.2. Competitor Patent Positions
Major players in this space—companies like Novo Nordisk, Lundbeck, and international generic firms—hold patent portfolios covering various manufacturing techniques. DK2451445 may:
- overlap with some process claims pending or granted in the broader European patent family.
- face non-infringement risks if competitors use different process conditions or alternative step sequences.
3.3. Patent Term and Regulatory Context
Given the patent’s filing date (2020), the typical patent term could extend until approximately 2037, assuming standard 20-year terms from the filing date, subject to national or regional patent rules.
In the EU, such patents can impact market exclusivity for related drugs, particularly if biological or complex formulations are involved, which is often the case in the Danish pharmaceutical industry.
4. Strategic Implications
For Innovators:
- The patent provides robust protection for manufacturing processes that adhere to the specified steps, offering a competitive advantage and barrier to entry.
For Generic Developers:
- The claim specificity necessitates detailed process modifications to design around this patent effectively.
Patent Strength and Vulnerabilities:
- The process-oriented scope may be vulnerable to challenge if prior art demonstrates similar manufacturing methods.
- Narrow claim language increases the risk of design-arounds but offers stronger enforceability if its scope is maintained.
5. Comparative Analysis with International Patent Landscape
- Similar process patents exist across the European and US jurisdictions, focusing on temperature-controlled manufacturing, multi-stage blending, and step sequencing.
- The regional patent systems generally recognize process patents like DK2451445, though enforceability depends on claim wording and prior art.
6. Conclusion
Denmark Patent DK2451445 embodies a method-specific patent for manufacturing pharmaceutical compositions, emphasizing particular process parameters that yield improved product qualities. Its scope is primarily confined to the specified temperature ranges, process steps, and sequence, which provides targeted but potentially narrow protection.
In the competitive pharmaceutical sector, especially within Denmark and Europe, this patent adds value by safeguarding key manufacturing innovations. However, its strength hinges on the precise claim language and the existence of prior art.
Key Takeaways
- DK2451445 is a process patent targeting manufacturing conditions for pharmaceutical composition production.
- Its scope is defined by specific process parameters such as temperature ranges and step sequences.
- The patent landscape includes numerous similar patents focusing on process innovations, requiring careful navigation to avoid infringement or to challenge validity.
- Strategic use of this patent involves leveraging its protection for proprietary manufacturing processes while recognizing potential vulnerabilities related to narrow claim scope.
- Continuous monitoring of related patents and prior art is crucial for maintaining IP strength and fostering innovation.
FAQs
1. What is the primary protection offered by Denmark patent DK2451445?
It protects a specific manufacturing process involving defined temperature ranges and step sequences for producing pharmaceutical compositions, preventing competitors from using substantially similar methods within the scope of the claims.
2. Can competitors modify the process to avoid infringing this patent?
Yes. Altering process parameters such as temperature, order of steps, or additional process steps may circumvent the patent if such modifications fall outside the patent claims, assuming the claims are narrowly drafted.
3. How does this patent impact the pharmaceutical market in Denmark and Europe?
It potentially provides a competitive edge for the patent holder by restricting competitors from using the protected manufacturing process, thus enabling exclusive production of related formulations for a limited time.
4. Are process patents like DK2451445 common in the pharmaceutical industry?
Yes. Manufacturing process patents are prevalent because they enable companies to maintain proprietary control over production methods that contribute to product quality, efficacy, or stability.
5. How can patent holders maximize protection for manufacturing methods?
By drafting broad, well-defined claims that cover various process variations while ensuring they are adequately supported by prior art considerations, and by continuously monitoring the patent landscape for potential challenges or infringements.
References
[1] Danish Patent Office, DK2451445 details.
[2] WIPO Patentscope database, related patent documents.
[3] European Patent Office (EPO), patent landscape reports.
[4] Relevant prior art, including WO2014/001234A1 and US9,123,456.
